# Berobenatide: Pfizer's monthly GLP-1 shot, known so far

Source: https://pepvault.app/guides/berobenatide-explained

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far

Reviewed November 2026 20 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Berobenatide (PF-08653944, MET-097i) is Pfizer's monthly GLP-1 shot in phase 3: how it lasts, every phase 2 number, all 24 trials, and when results are due.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 20
- **Questions:** 7
- **Compounds:** 3

## The short answer

Berobenatide (PF-08653944, first called MET-097i) is Pfizer's experimental GLP-1 shot, built to last long enough for one injection a month. It is approved nowhere. In phase 2, weight fell up to 14.1% more than on placebo after 28 weekly shots, and 12.3% more when people moved to monthly shots. The first phase 3 trial, VESPER-4, ends its main measurement in September 2027 (registry estimate).

Every number checked at its primary source · Nov 20, 2026 · [20 sources](https://pepvault.app/guides/berobenatide-explained#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Early: company-run phase 2 trials in people (VESPER-1 with results posted on ClinicalTrials.gov; VESPER-2 and VESPER-3 from Pfizer's releases), no journal paper yet, and phase 3 under way with no result. Approved nowhere.

## What is berobenatide?

Berobenatide is an experimental weight-loss injection, a GLP-1 receptor agonist: a drug that switches on the body's receptor for GLP-1, the gut hormone that helps set appetite, the same receptor Wegovy and Zepbound act on. It was made by Metsera, a New York biotech, as **MET-097i** (MET097 in the trial records). Pfizer bought Metsera and now develops it as **PF-08653944**, shortened to PF'3944. Berobenatide is its generic name, the international nonproprietary name (INN) the World Health Organization proposed in 2025 and recommended in 2026[20](https://pepvault.app/guides/berobenatide-explained#source-20); Pfizer has used it since June 2026[7](https://pepvault.app/guides/berobenatide-explained#source-7).

Pfizer won it after a bidding contest. Novo Nordisk, the maker of Wegovy, made a rival offer, which Metsera disclosed on October 30, 2025, and Pfizer raised its own from $47.50 to $65.60 a share in cash, plus up to $20.65 more tied to milestones[2](https://pepvault.app/guides/berobenatide-explained#source-2) [3](https://pepvault.app/guides/berobenatide-explained#source-3). The deal closed on November 13, 2025, at an enterprise value of about $7.0 billion[1](https://pepvault.app/guides/berobenatide-explained#source-1).

As of November 20, 2026, berobenatide is approved nowhere and given only inside Pfizer's clinical trials. No result has been published in a journal yet; the numbers below come from the trial registry and the two companies' own reports.

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

PepVault can hold a dose every 28 days as easily as a weekly one, and the reminder comes on the day it falls due, so a monthly shot is not lost between months.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How does berobenatide work?

Like every GLP-1 drug, it lowers appetite, makes a meal feel filling sooner and slows how fast the stomach empties. Two design choices set it apart[4](https://pepvault.app/guides/berobenatide-explained#source-4).

- **It is fully biased.** When a GLP-1 receptor is switched on it sends a signal (through a messenger called cAMP) and also pulls in a protein called beta-arrestin, which dulls the receptor and draws it into the cell. Berobenatide is built to send the signal without pulling in beta-arrestin, so the receptor keeps working over time[4](https://pepvault.app/guides/berobenatide-explained#source-4).
- **It carries a lipid tail.** The peptide is a reworked exendin-4, the Gila monster peptide behind the older drug exenatide. Metsera's HALO method fixes a fatty chain to its tail end, so it rides on albumin, a blood protein, and the body clears it slowly[4](https://pepvault.app/guides/berobenatide-explained#source-4) [20](https://pepvault.app/guides/berobenatide-explained#source-20).

The result is a long half-life, the time the body takes to clear half a dose: about 15 to 16 days in Metsera's first human trial[4](https://pepvault.app/guides/berobenatide-explained#source-4), against about one week for semaglutide and five to six days for tirzepatide[18](https://pepvault.app/guides/berobenatide-explained#source-18) [19](https://pepvault.app/guides/berobenatide-explained#source-19). Pfizer says a monthly dose fits in a 0.5 mL injection[7](https://pepvault.app/guides/berobenatide-explained#source-7).

## Why does monthly dosing matter?

A monthly shot means 12 injections a year instead of 52, and a missed week matters less. The long half-life also means the drug lingers. In Metsera's first trial, people who took five weekly 1.2 mg shots were 7.5% lighter on day 36, 8.1% on day 57, and still 7.5% lighter on day 85, eight weeks after the last shot; the placebo group's change was under 1% throughout[4](https://pepvault.app/guides/berobenatide-explained#source-4). That was a small, short trial, but it is the behaviour a monthly drug needs.

In the trials, people start weekly and then move to monthly. VESPER-3 gave weekly shots for 12 weeks, with up to two steps up, then one shot a month: 3.2 mg or 4.8 mg in the two schedules Pfizer chose for phase 3, where it planned to add a higher 9.6 mg monthly dose[6](https://pepvault.app/guides/berobenatide-explained#source-6). These are trial doses, not a regimen to follow. Phase 3 also keeps a weekly version, so berobenatide may come both ways.

<!--promo-->

PepVault can hold a dose every 28 days as easily as a weekly one, and the reminder comes on the day it falls due, so a monthly shot is not lost between months. [Set reminders in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-berobenatide-explained-inline&mt=8)

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

## How much weight did people lose on berobenatide?

Up to about 14% more than placebo in 28 weeks, with no plateau yet. VESPER-1 gave 239 adults a weekly shot at a fixed dose from the first week, with no slow climb, for 28 weeks; on 1.2 mg, weight fell 12.5% while the placebo group gained 1.7%[8](https://pepvault.app/guides/berobenatide-explained#source-8). Each figure below is the change while people stayed on treatment (the efficacy measure); counting everyone who started, including those who stopped (the treatment-policy measure), the numbers run lower, as VESPER-3's second row shows.

| Trial | People | Weeks | Dosing | Weight change | Beyond placebo |
| --- | --- | --- | --- | --- | --- |
| Phase 1/2, part C[4](https://pepvault.app/guides/berobenatide-explained#source-4) [9](https://pepvault.app/guides/berobenatide-explained#source-9) | 120 | 12 | Weekly, 0.6 to 1.2 mg | Not reported | 7.2% to 11.3% (preliminary) |
| VESPER-1[5](https://pepvault.app/guides/berobenatide-explained#source-5) [8](https://pepvault.app/guides/berobenatide-explained#source-8) | 239 | 28 | Weekly, 0.4 to 1.2 mg, no step-up | -6.4% to -12.5% (placebo +1.7%) | 8.1 to 14.1 points |
| VESPER-1 extension[7](https://pepvault.app/guides/berobenatide-explained#source-7) | People moved from placebo | 32 on the drug | Weekly, 2.4 mg | -15.9% (average, no placebo group) | Not applicable |
| VESPER-3, while on treatment[6](https://pepvault.app/guides/berobenatide-explained#source-6) [11](https://pepvault.app/guides/berobenatide-explained#source-11) | 268 | 28 | Weekly 12 weeks, then monthly | Not reported | 10.0 and 12.3 points |
| VESPER-3, counting everyone[6](https://pepvault.app/guides/berobenatide-explained#source-6) | 268 | 28 | Weekly 12 weeks, then monthly | Not reported | 8.4 and 10.5 points |

The VESPER-3 pairs are the two monthly schedules that went into phase 3, and Pfizer reports that weight was still falling at week 28[6](https://pepvault.app/guides/berobenatide-explained#source-6). In VESPER-2, in 133 people with type 2 diabetes, HbA1c (the three-month blood sugar average) fell 2.2 points on 1.6 mg weekly at 28 weeks, against 0.2 on placebo[7](https://pepvault.app/guides/berobenatide-explained#source-7) [10](https://pepvault.app/guides/berobenatide-explained#source-10). These results cover 28 weeks (VESPER-3 ran on to week 64 and ended in October 2026, with those numbers not yet released[11](https://pepvault.app/guides/berobenatide-explained#source-11)); the approved weekly drugs were measured over 68 to 72 weeks, so a fair comparison waits for phase 3.

## What side effects did berobenatide cause in trials?

The usual GLP-1 ones, in the stomach and gut, mostly mild or moderate[6](https://pepvault.app/guides/berobenatide-explained#source-6). VESPER-1 started people on their full dose with no step-up. On 1.2 mg, 24 of 48 people reported nausea at some point, against 13 of 48 on placebo; vomiting 12 against 6; diarrhea 11 against 5[8](https://pepvault.app/guides/berobenatide-explained#source-8). Only 2 of the 239 people stopped treatment because of side effects[5](https://pepvault.app/guides/berobenatide-explained#source-5).

Stepping up helped. In VESPER-3's first 12 weeks, the schedule that climbed 0.4, 0.8 then 1.2 mg had about 13 percentage points more nausea than placebo, 11 more vomiting, and no more diarrhea[5](https://pepvault.app/guides/berobenatide-explained#source-5). Across the two phase 3 schedules, five people stopped for side effects in the weekly weeks and five in the monthly weeks, of about 108; none stopped on placebo[6](https://pepvault.app/guides/berobenatide-explained#source-6).

**When to get help** On any GLP-1 drug, severe stomach pain that does not ease, sometimes reaching the back, or vomiting that stops you keeping fluids down is a reason to call your clinician the same day[18](https://pepvault.app/guides/berobenatide-explained#source-18).

## Which berobenatide trials are in the registry?

Twenty-four records name it under one of its names as of November 20, 2026, all sponsored by Pfizer or by Metsera as Pfizer's subsidiary[17](https://pepvault.app/guides/berobenatide-explained#source-17). Pfizer had said it would run 10 phase 3 trials in 2026[6](https://pepvault.app/guides/berobenatide-explained#source-6); the registry now lists 13. Dates are primary completion, per ClinicalTrials.gov: when the main measurement ends, not when results come out. "Est." marks the sponsor's estimate.

| Phase 3 trial | Who | People | Primary completion | Status |
| --- | --- | --- | --- | --- |
| VESPER-4, weekly (NCT07311850)[12](https://pepvault.app/guides/berobenatide-explained#source-12) | Obesity or overweight, no diabetes | 3,578 | Sep 2027 (est.) | Active, not recruiting |
| VESPER-5, weekly (NCT07400653)[13](https://pepvault.app/guides/berobenatide-explained#source-13) | With type 2 diabetes | 1,078 | Oct 2027 (est.) | Active, not recruiting |
| VESPER-6, monthly (NCT07595549)[14](https://pepvault.app/guides/berobenatide-explained#source-14) | Obesity or overweight | 954 (planned) | May 2028 (est.) | Recruiting |
| VESPER-SWITCH, monthly (NCT07845500)[15](https://pepvault.app/guides/berobenatide-explained#source-15) | Now on weekly semaglutide or tirzepatide | 660 (planned) | Feb 2028 (est.) | Recruiting |
| Weekly, China (NCT07792954) | Chinese adults | 300 (planned) | Mar 2028 (est.) | Recruiting |
| Monthly, China (NCT07874633) | Chinese adults | 432 (planned) | Jun 2028 (est.) | Recruiting |
| VESPER-JW, weekly (NCT07794761) | Adults in Japan | 180 (planned) | Mar 2029 (est.) | Recruiting |
| VESPER-JM, monthly (NCT07794774) | Adults in Japan | 197 (planned) | Feb 2029 (est.) | Recruiting |
| VESPER-OSA 1, monthly (NCT07823608) | Sleep apnea, using a breathing machine | 258 (planned) | Apr 2028 (est.) | Recruiting |
| VESPER-OSA 2, monthly (NCT07881757) | Sleep apnea, no breathing machine | 258 (planned) | Jun 2028 (est.) | Recruiting |
| VESPER-OA 1, monthly (NCT07919678) | Knee osteoarthritis | 656 (planned) | Aug 2028 (est.) | Recruiting |
| VESPER-OA 2, weekly (NCT07915609) | Knee osteoarthritis | 756 (planned) | Aug 2028 (est.) | Recruiting |
| VESPER-SUI (NCT07932925) | Women with stress urine leakage | 900 (planned) | Oct 2028 (est.) | Recruiting |

| Earlier or smaller trial | Phase | People | Primary completion | Status |
| --- | --- | --- | --- | --- |
| First human trial (NCT06857617)[9](https://pepvault.app/guides/berobenatide-explained#source-9) | 1/2 | 120 | Jan 2025 | Completed |
| VESPER-1 (NCT06712836)[8](https://pepvault.app/guides/berobenatide-explained#source-8) | 2b | 239 | Jul 2025 | Completed, results posted |
| VESPER-2, type 2 diabetes (NCT06897202)[10](https://pepvault.app/guides/berobenatide-explained#source-10) | 2b | 133 | Dec 2025 | Completed |
| VESPER-3, weekly then monthly (NCT06973720)[11](https://pepvault.app/guides/berobenatide-explained#source-11) | 2b | 268 | Dec 2025 | Completed |
| With the amylin drug MET-233i (NCT06924320) | 1/2 | 201 | Sep 2026 | Completed |
| SOLIS-1, with amylin drug PF-08653945 (NCT07575932)[16](https://pepvault.app/guides/berobenatide-explained#source-16) | 2b | 940 | Aug 2027 (est.) | Active, not recruiting |
| Injection sites (NCT07400679) | 1 | 48 | Jul 2026 | Completed |
| Stomach emptying (NCT07508241) | 1 | 22 | Jan 2027 (est.) | Active, not recruiting |
| Single dose, China (NCT07845513) | 1 | 11 | Feb 2027 (est.) | Active, not recruiting |
| Delivery devices (NCT07876531) | 1 | 144 (planned) | Apr 2027 (est.) | Recruiting |
| Liver function (NCT07519135) | 1 | 26 (planned) | Jul 2027 (est.) | Recruiting |

The weight trials measure the change in body weight at 64 weeks (VESPER-4 and -5) or 72 weeks (VESPER-6)[12](https://pepvault.app/guides/berobenatide-explained#source-12) [13](https://pepvault.app/guides/berobenatide-explained#source-13) [14](https://pepvault.app/guides/berobenatide-explained#source-14). VESPER-SWITCH asks whether people who already lost weight on a weekly shot keep it off after moving to monthly berobenatide, measured at 32 weeks[15](https://pepvault.app/guides/berobenatide-explained#source-15). The amylin pairing matters too: amylin is a second gut hormone that adds fullness, and Pfizer plans berobenatide as the base of combination shots[6](https://pepvault.app/guides/berobenatide-explained#source-6) [16](https://pepvault.app/guides/berobenatide-explained#source-16).

## When will berobenatide's next results come out?

The first phase 3 answers can come from late 2027. VESPER-4, the large weekly trial, has an estimated primary completion of September 21, 2027, and VESPER-5 of October 12, 2027, both Pfizer's estimates on ClinicalTrials.gov[12](https://pepvault.app/guides/berobenatide-explained#source-12) [13](https://pepvault.app/guides/berobenatide-explained#source-13); results usually follow some weeks later. SOLIS-1, the amylin combination, finishes its main measurement in August 2027 (registry estimate)[16](https://pepvault.app/guides/berobenatide-explained#source-16). The monthly phase 3 answer, VESPER-6, follows, estimated for May 2028[14](https://pepvault.app/guides/berobenatide-explained#source-14).

**Has a phase 3 trial reported yet?** Not as of November 20, 2026. Pfizer has given no filing or approval date: its June 2026 release names none[7](https://pepvault.app/guides/berobenatide-explained#source-7). This page is updated when the first result lands.

<!--promo-->

If you take a weekly GLP-1 today, PepVault keeps your weight log and trend beside your doses, so any later switch, to a monthly shot or anything else, starts from your own numbers. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-berobenatide-explained-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Pfizer. Pfizer completes acquisition of Metsera. November 13, 2025. [pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-metsera)
2. Metsera, Inc. Form 8-K: receipt of an unsolicited proposal from Novo Nordisk. October 30, 2025. [sec.gov](https://www.sec.gov/Archives/edgar/data/2040807/000119312525257435/d54035d8k.htm)
3. Metsera, Inc. Form 8-K: Amendment No. 1 to the Agreement and Plan of Merger with Pfizer Inc. November 10, 2025. [sec.gov](https://www.sec.gov/Archives/edgar/data/2040807/000119312525273292/d50740d8k.htm)
4. Metsera, Inc. Annual report on Form 10-K for the year ended December 31, 2024 (MET-097i, the HALO platform and the phase 1/2 trial). March 26, 2025. [sec.gov](https://www.sec.gov/Archives/edgar/data/2040807/000095017025044778/mtsr-20241231.htm)
5. Metsera. Positive phase 2b results for MET-097i: VESPER-1 topline and VESPER-3 interim tolerability (Form 8-K, Exhibit 99.1). September 29, 2025. [sec.gov](https://www.sec.gov/Archives/edgar/data/2040807/000119312525223440/d943312dex991.htm)
6. Pfizer. Pfizer's ultra-long-acting injectable GLP-1 RA shows robust and continued weight loss with monthly dosing in phase 2b trial (VESPER-3). February 3, 2026. [pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust)
7. Pfizer. Robust phase 2b efficacy and favorable tolerability support monthly dosing for Pfizer's GLP-1 RA berobenatide. June 6, 2026. [pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/robust-phase-2b-efficacy-and-favorable-tolerability-support)
8. ClinicalTrials.gov. NCT06712836: VESPER-1, once-weekly MET097 (berobenatide) in adults with obesity or overweight, posted results. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712836)
9. ClinicalTrials.gov. NCT06857617: phase 1/2 study of MET097 in adults with obesity or overweight. Metsera, a wholly owned subsidiary of Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06857617)
10. ClinicalTrials.gov. NCT06897202: VESPER-2, once-weekly MET097 in adults with obesity or overweight and type 2 diabetes. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06897202)
11. ClinicalTrials.gov. NCT06973720: VESPER-3, once-weekly switching to once-monthly MET097. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06973720)
12. ClinicalTrials.gov. NCT07311850: VESPER-4, MET097 (PF-08653944) once weekly in people with overweight or obesity. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311850)
13. ClinicalTrials.gov. NCT07400653: VESPER-5, PF-08653944 in people with overweight or obesity and type 2 diabetes. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400653)
14. ClinicalTrials.gov. NCT07595549: VESPER-6, once-monthly berobenatide (PF-08653944) in adults with overweight or obesity. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595549)
15. ClinicalTrials.gov. NCT07845500: VESPER-SWITCH, switching to monthly berobenatide in adults on weekly semaglutide or tirzepatide. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500)
16. ClinicalTrials.gov. NCT07575932: SOLIS-1, PF-08653945 and PF-08653944 alone or in combination. Pfizer. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575932)
17. ClinicalTrials.gov. All studies naming berobenatide, PF-08653944 or MET097, read November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/search?term=berobenatide%20OR%20PF-08653944%20OR%20MET097)
18. Wegovy (semaglutide) prescribing information. Novo Nordisk. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
19. Zepbound (tirzepatide) prescribing information. Eli Lilly. DailyMed. [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
20. World Health Organization. Recommended INN: List 95 (berobenatide; first proposed in List 133, 2025). WHO Drug Information, Vol. 40, No. 1, 2026. [cdn.who.int](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/rl95.pdf)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)

Every GLP-1-family drug in phase 2 or 3 as of November 20, 2026: company, how it works, its key trial and the ClinicalTrials.gov completion date.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [MariTide Studied range: 21–420 mg](https://pepvault.app/peptides/maritide)

## Related guides

- Guide · GLP-1s

  ### [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)

  No monthly GLP-1 shot is approved yet. MariTide and berobenatide are in phase 3: how one shot lasts a month, what phase 2 found, and when results are due.

  Read the guide
- Guide · GLP-1s

  ### [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)

  Aleniglipron is Structure Therapeutics' daily GLP-1 pill in testing: its phase 2 numbers, every trial, and what its shot-to-pill SWITCH trial must beat.

  Read the guide
- Guide · GLP-1s

  ### [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)

  What each trial tested for keeping weight off after a GLP-1: staying on, a lower dose, switching to a pill and exercise, with every result in one by-drug table.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Half-life](https://pepvault.app/glossary/half-life)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [HbA1c (A1C)](https://pepvault.app/glossary/hba1c)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
